Choueiri, T. K., Hessel, C., Halabi, S., Sanford, B., Michaelson, M. D., Hahn, O., . . . Morris, M. J. (2018). Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125]. Eur J Cancer.
Stile di citazione ChicagoChoueiri, Toni K., et al. "Corrigendum to ‘Cabozantinib Versus Sunitinib As Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-free Survival By Independent Review and Overall Survival Update’ [Eur J Cancer 94 (May 2018) 115–125]." Eur J Cancer 2018.
Citazione MLAChoueiri, Toni K., et al. "Corrigendum to ‘Cabozantinib Versus Sunitinib As Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-free Survival By Independent Review and Overall Survival Update’ [Eur J Cancer 94 (May 2018) 115–125]." Eur J Cancer 2018.